文献速递临床生化临床免疫质量管理与危急值

女性雄激素检测中生化高雄激素血症分类随检测方法而变:CLIA与LC-MS/MS在常用临床决策阈值下的比较

Assay-dependent reclassification of biochemical hyperandrogenism in female androgen testing: CLIA versus LC-MS/MS under common clinical decision thresholds.
PubMed 文献 · Clin Chim Acta · 2026-09-16

该研究回顾495份女性生殖内分泌样本,对同一样本分别用常规化学发光免疫分析(CLIA)与液相色谱-串联质谱(LC-MS/MS)测定睾酮和雄烯二酮,并套用常用报告阈值(睾酮>2.5 nmol/L、雄烯二酮>10 nmol/L)进行生化高雄激素血症分类。结果显示两种方法分类不一致,且再分类方向随分析物而异:LC-MS/MS提高睾酮阳性率,CLIA提高雄烯二酮及联合阳性率。

要点

  • 同一 female 样本在CLIA与LC-MS/MS下可被判为不同生化高雄激素血症分类,不一致率为睾酮10.7%、雄烯二酮32.7%、任一阳性32.5%。
  • LC-MS/MS使睾酮阳性率由CLIA的2.6%升至12.1%,而CLIA使雄烯二酮阳性率高于LC-MS/MS(49.5% vs 37.0%)。
  • 接近决策阈值的女性雄激素结果或与临床表现不符时,应结合检测方法解读。

核心结论

  • 在女性生殖内分泌队列中,对CLIA与LC-MS/MS结果套用常用决策阈值,未能得到相同的生化高雄激素血症分类。
  • 再分类方向取决于分析物:LC-MS/MS提高睾酮阳性分类,CLIA提高雄烯二酮及联合阳性分类。
  • 研究未定义LC-MS/MS专用切点,但提示决策阈值附近或与临床不符的女性雄激素结果应结合检测方法解读。

研究设计与样本

  • 回顾性分析495份女性生殖内分泌样本,均具有CLIA与LC-MS/MS配对的睾酮和雄烯二酮结果。
  • 对两种平台均套用常规报告阈值:睾酮>2.5 nmol/L、雄烯二酮>10 nmol/L。
  • 生化高雄激素血症按单用睾酮、单用雄烯二酮或任一分析物阳性分类;两平台分类不同即判为不一致。
  • 敏感性分析排除距切点±10%、±20%、±30%范围内的样本。

主要发现

  • 睾酮阳性:CLIA为13/495(2.6%),LC-MS/MS为60/495(12.1%)。
  • 雄烯二酮阳性:CLIA为245/495(49.5%),LC-MS/MS为183/495(37.0%)。
  • 联合定义阳性:CLIA为246/495(49.7%),LC-MS/MS为189/495(38.2%)。
  • 分类不一致:睾酮分类53例(10.7%),雄烯二酮分类162例(32.7%),任一分析物分类161例(32.5%)。
  • 排除接近阈值样本后不一致减少,但±30%排除后仍分别残留2.8%、11.3%、8.1%。

关键数值与推荐

  • 常规报告阈值:睾酮>2.5 nmol/L,雄烯二酮>10 nmol/L,同时套用于CLIA与LC-MS/MS。
  • 生化高雄激素血症分类定义:单用睾酮阳性、单用雄烯二酮阳性或任一分析物阳性。
  • 敏感性分析排除范围:距切点±10%、±20%、±30%。

临床怎么用

  • 解读女性睾酮和雄烯二酮结果时,应知晓所用检测方法(CLIA或LC-MS/MS),尤其在结果接近决策阈值时。
  • 对接近阈值或与临床表现矛盾的女性雄激素结果,不宜仅凭二分类阳性/阴性下结论,应结合检测方法判断。
  • 方法间再分类方向因分析物不同,联合评估睾酮与雄烯二酮时需注意CLIA与LC-MS/MS的差异。

局限性

  • 本研究为单中心回顾性队列,样本为女性生殖内分泌样本。
  • 研究未定义LC-MS/MS专用切点。
  • 原文未报告纳入样本的具体临床诊断构成及排除标准细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Female testosterone and androstenedione results are commonly interpreted as either above or below a reporting threshold. This binary reading is practical, but it also means that assay differences may become classification differences. We investigated whether routine chemiluminescent immunoassay (CLIA) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) give the same biochemical hyperandrogenism classification when commonly used decision limits are applied to paired female androgen results. METHODS: We reviewed 495 female reproductive endocrine samples with paired CLIA and LC-MS/MS results for testosterone and androstenedione. The routine thresholds used in reporting, testosterone >2.5 nmol/L and androstenedione >10 nmol/L, were applied to both platforms. Biochemical hyperandrogenism was classified by testosterone alone, androstenedione alone, or either analyte being positive. Discordance referred to the situation where two platforms assigned different classifications to an identical sample. Sensitivity analyses were performed by excluding samples located within ±10%, ±20%, or ± 30% of the cut-off thresholds. RESULTS: The two analytes did not show the same assay pattern. For testosterone, positivity was low with CLIA, involving 13 of 495 samples (2.6%), but increased to 60 samples (12.1%) with LC-MS/MS. Androstenedione was in the opposite direction: 245 samples (49.5%) were positive by CLIA, compared with 183 samples (37.0%) by LC-MS/MS. Because androstenedione contributed most of the positive classifications, the combined definition also gave a higher positivity rate with CLIA than with LC-MS/MS [246/495 (49.7%) vs. 189/495 (38.2%)]. The resulting mismatch was 53 samples (10.7%) for testosterone-based classification, 162 (32.7%) for androstenedione-based classification, and 161 (32.5%) when either analyte was considered. Removing samples close to the thresholds reduced the mismatch, but some discordance remained even after the ±30% exclusion: 2.8%, 11.3%, and 8.1%, respectively. CONCLUSIONS: In this female reproductive endocrine cohort, applying common decision thresholds to CLIA and LC-MS/MS results did not produce the same biochemical hyperandrogenism classification. The direction of reclassification depended on the analyte: LC-MS/MS increased testosterone-based positivity, whereas CLIA increased androstenedione-based and combined positivity. The findings do not define LC-MS/MS-specific cut-offs, but they show why female androgen results near decision limits-or results that conflict with the clinical picture-should be interpreted with the assay method in mind.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Zhang X, Xu H, Liu L, et al. Assay-dependent reclassification of biochemical hyperandrogenism in female androgen testing: CLIA versus LC-MS/MS under common clinical decision thresholds. Clin Chim Acta. 2026. PMID: 42749070. doi:10.1016/j.cca.2026.121347

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。